Immunotherapy Based on Dendritic Cell-Targeted/-Derived Extracellular Vesicles-A Novel Strategy for Enhancement of the Anti-tumor Immune Response

被引:98
作者
Markov, Oleg [1 ]
Oshchepkova, Anastasiya [1 ]
Mironova, Nadezhda [1 ]
机构
[1] RAS, Inst Chem Biol & Fundamental Med SB, Lab Nucle Acids Biochem, Novosibirsk, Russia
来源
FRONTIERS IN PHARMACOLOGY | 2019年 / 10卷
基金
俄罗斯科学基金会; 俄罗斯基础研究基金会;
关键词
dendritic cells; extracellular vesicles; exosomes; tumor; anti-tumor vaccines; EXOSOME-MEDIATED DELIVERY; IN-VITRO; TUMOR-ANTIGENS; ENGINEERED EXOSOMES; EFFICIENT INDUCTION; CTL RESPONSES; SIRNA; RECEPTOR; MICROVESICLES; VACCINE;
D O I
10.3389/fphar.2019.01152
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Dendritic cell (DC)-based anti-tumor vaccines have great potential for the treatment of cancer. To date, a large number of clinical trials involving DC-based vaccines have been conducted with a view to treating tumors of different histological origins. However, DC-based vaccines had several drawbacks, including problems with targeted delivery of tumor antigens to DCs and prolong storage of cellular vaccines. Therefore, the development of other immunotherapeutic approaches capable of enhancing the immunogenicity of existing DC-based vaccines or directly triggering anti-tumor immune responses is of great interest. Extracellular vesicles (EVs) are released by almost all types of eukaryotic cells for paracrine signaling. EVs can interact with target cells and change their functional activity by delivering different signaling molecules including mRNA, non-coding RNA, proteins, and lipids. EVs have potential benefits as natural vectors for the delivery of RNA and other therapeutic molecules targeted to DCs, T-lymphocytes, and tumor cells; therefore, EVs are a promising entity for the development of novel cell-free anti-tumor vaccines that may be a favourable alternative to DC-based vaccines. In the present review, we discuss the anti-tumor potential of EVs derived from DCs, tumors, and other cells. Methods of EV isolation are systematized, and key molecules carried by EVs that are necessary for the activation of a DC-mediated anti-tumor immune response are analyzed with a focus on the RNA component of EVs. Characteristics of anti-tumor immune responses induced by EVs in vitro and in vivo are reviewed. Finally, perspectives and challenges with the use of EVs for the development of anti-tumor cell-free vaccines are considered.
引用
收藏
页数:24
相关论文
共 133 条
[1]   Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes [J].
Alvarez-Erviti, Lydia ;
Seow, Yiqi ;
Yin, HaiFang ;
Betts, Corinne ;
Lakhal, Samira ;
Wood, Matthew J. A. .
NATURE BIOTECHNOLOGY, 2011, 29 (04) :341-U179
[2]   Tumor-derived exosomes:: a new source of tumor rejection antigens [J].
André, F ;
Scharz, NEC ;
Chaput, N ;
Flament, C ;
Raposo, G ;
Amigorena, S ;
Angevin, E ;
Zitvogel, L .
VACCINE, 2002, 20 :A28-A31
[3]  
[Anonymous], 2019, CELLS-BASEL, DOI DOI 10.3390/CELLS8040307
[4]   Engineered exosomes emerging from muscle cells break immune tolerance to HER2 in transgenic mice and induce antigen-specific CTLs upon challenge by human dendritic cells [J].
Anticoli, Simona ;
Arico, Eleonora ;
Arenaccio, Claudia ;
Manfredi, Francesco ;
Chiozzini, Chiara ;
Olivetta, Eleonora ;
Ferrantelli, Flavia ;
Lattanzi, Laura ;
D'Urso, Maria Teresa ;
Proietti, Enrico ;
Federico, Maurizio .
JOURNAL OF MOLECULAR MEDICINE-JMM, 2018, 96 (02) :211-221
[5]   Phenotypical and functional evaluation of dendritic cells after exosomal delivery of miRNA-155 [J].
Asadirad, Ali ;
Hashemi, Seyed Mahmoud ;
Baghaei, Kaveh ;
Ghanbarian, Hossein ;
Mortaz, Esmaeil ;
Zali, Mohammad Reza ;
Amani, Davar .
LIFE SCIENCES, 2019, 219 :152-162
[6]   Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid malignancies, on supportive care [J].
Bapsy, Poonamalle Parthasarathy ;
Sharan, Bandana ;
Kumar, Chaitanya ;
Das, Rajeev Patrick ;
Rangarajan, Bharath ;
Jain, Minish ;
Attili, Venkata Sathya Suresh ;
Subramanian, Sundaram ;
Aggarwal, Shyam ;
Srivastava, Mala ;
Vaid, Ashok .
CYTOTHERAPY, 2014, 16 (02) :234-244
[7]   Using exosomes, naturally-equipped nanocarriers, for drug delivery [J].
Batrakova, Elena V. ;
Kim, Myung Soo .
JOURNAL OF CONTROLLED RELEASE, 2015, 219 :396-405
[8]   Interleukin 3-receptor targeted exosomes inhibit in vitro and in vivo Chronic Myelogenous Leukemia cell growth [J].
Bellavia, Daniele ;
Raimondo, Stefania ;
Calabrese, Giovanna ;
Forte, Stefano ;
Cristaldi, Marta ;
Patinella, Agostina ;
Memeo, Lorenzo ;
Manno, Mauro ;
Raccosta, Samuele ;
Diana, Patrizia ;
Cirrincione, Girolamo ;
Giavaresi, Gianluca ;
Monteleone, Francesca ;
Fontana, Simona ;
De Leo, Giacomo ;
Alessandro, Riccardo .
THERANOSTICS, 2017, 7 (05) :1333-1345
[9]   Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC [J].
Besse, Benjamin ;
Charrier, Melinda ;
Lapierre, Valerie ;
Dansin, Eric ;
Lantz, Olivier ;
Planchard, David ;
Le Chevalier, Thierry ;
Livartoski, Alain ;
Barlesik, Fabrice ;
Laplanche, Agnes ;
Ploix, Stephanie ;
Vimond, Nadege ;
Peguillet, Isabelle ;
Thery, Clotilde ;
Lacroix, Ludovic ;
Zoernig, Inka ;
Dhodapkar, Kavita ;
Dhodapkar, Madhav ;
Viaud, Sophie ;
Soria, Jean-Charles ;
Reiners, Katrin S. ;
von Strandmann, Elke Pogge ;
Vely, Frederic ;
Rusakiewicz, Sylvie ;
Eggermont, Alexander ;
Pitt, Jonathan M. ;
Zitvogel, Laurence ;
Chaput, Nathalie .
ONCOIMMUNOLOGY, 2016, 5 (04)
[10]   Exosomes from Dendritic Cells Loaded with Chaperone-Rich Cell Lysates Elicit a Potent T Cell Immune Response Against Intracranial Glioma in Mice [J].
Bu, Ning ;
Wu, Haiqin ;
Zhang, Guilian ;
Zhan, Shuqin ;
Zhang, Ru ;
Sun, Hong ;
Du, Yun ;
Yao, Li ;
Wang, Huqing .
JOURNAL OF MOLECULAR NEUROSCIENCE, 2015, 56 (03) :631-643